Barwon Health-The Geelong Hospital

Geelong, Victoria 3220

0 studies enrolling now · 14 studies all time

What they study most

B-cell Lymphoid Malignancies, B-cell Malignancies, Breast Cancer, Cardiovascular Disease, Cardiovascular Risk, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Heart Failure, Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, Type 1 Diabetes Mellitus, Type 2 Diabetes, Type 2 Diabetes Mellitus

Studies at this site

• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation — Running, not enrolling
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — Running, not enrolling
• Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes — Completed
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec — Completed
• Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies — Running, not enrolling
• Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) — Completed
• A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) — Completed
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies — Completed
• A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes — Completed
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early